Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: sotorasib, adagrasib, salirasib | 1.00 |
| trials ClinicalTrials.gov | 33 Parkinson's trials, 3 stopped | 0.93 |
| literature PubMed | 9 Parkinson's papers of 32,178 | 0.70 |
| pathways Reactome | 71 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 9748
Sealed predictions
- KRAS in dopamine neurons, braak-0.06 (p 0.870) → +0.05 (p 0.892)receipt 9755
Swarm cases
receipt 9755: KRAS in dopamine neurons, braak
- power
- full sample +0.12 (p 0.627, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.09 (p 0.715, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.09 (p 0.715, n 18). could be the mix.
- skeptic
- leave-one-out range +0.04 to +0.27, sign flips 0; without severely affected donors +0.12 (p 0.627, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KRAS in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts